Sarah Bennett
The COVID-19 pandemic has brought about an unprecedented global effort to develop a vaccine for the SARS-CoV-2 virus, with several countries racing to produce an effective solution. As of 2025, the COVID-19 vaccine is recommended annually, similar to the flu shot, with periodic updates to target new strains. While the original vaccine roll-out in 2021 was met with optimism, the ever-evolving nature of the virus means vaccine access and policy have become increasingly complex and, at times, confusing. Despite this, the vaccine remains an effective tool in preventing serious illness, hospitalisation, and death, and is recommended for those most at risk, including the elderly, immunocompromised, and pregnant people.
| Characteristics | Values |
|---|---|
| Countries working on a vaccine | China, Israel, America |
| Companies with approved vaccines | Pfizer-BioNTech, Moderna, Novavax |
| Number of clinical trial stages | 3 |
| Time taken for each stage | Months |
| Vaccine effectiveness | Very effective at preventing serious illness, hospitalisation and death |
| Vaccine safety | Safe for people who are pregnant or lactating, as well as those intending to become pregnant |
| Vaccine side effects | Vary and may last one to three days |
| People at risk | Those who are ages 65 and older, are at high risk for severe COVID-19, or have never received a COVID-19 vaccine |
| People recommended to discuss with a healthcare provider | Parents of children ages 6 months to 17 years |
Explore related products
$21.91 $29.95
What You'll Learn
- China, Israel and America are competing to make vaccines
- The Wuhan Academy of Military Medical Sciences has permission to test a potential formula
- The Israel Biological Research Institute has finished developing a vaccine, but it still requires testing
- The vaccine will need to go through three clinical trial stages
- The original COVID vaccines were tested on healthy volunteers
China, Israel and America are competing to make vaccines
Several countries, including China, Israel, and the United States, are competing to develop vaccines to combat the mutated coronavirus, also known as COVID-19. Each country is making strides in the race to create an effective vaccine, leveraging their scientific expertise and technological capabilities.
In China, biowarfare scientists from the Wuhan Academy of Military Medical Sciences have secured permission to test a potential vaccine formula. Led by military biowarfare expert Chen Wei, the Chinese team has been working on their vaccine research since January 26 and is confident in their ability to produce a large-scale vaccine if the trials are successful. Chen Wei emphasizes the importance of vaccines as a powerful weapon to end the coronavirus epidemic.
Israel is also making significant progress in the development of a COVID-19 vaccine. Researchers from the Israel Biological Research Institute are reportedly close to announcing the completion of their vaccine development. However, the process is not yet finalized, as a series of tests and experiments are still required to confirm the vaccine's effectiveness and safety. Israeli officials remain optimistic about their vaccine-making efforts, even as they acknowledge the challenges ahead.
The United States, a leader in medical research and innovation, is also actively pursuing vaccine development. The country has a history of producing effective vaccines, and its pharmaceutical industry is known for its rigorous testing and safety standards. The first person in the US to receive the vaccine was a 43-year-old mother of two, Jennifer Halle, who expressed her enthusiasm for contributing to the effort.
While the competition between these nations intensifies, the ultimate goal remains to develop a safe and effective vaccine to protect people's lives and health worldwide. Each country's efforts contribute to the global fight against the coronavirus pandemic, and their collaboration and sharing of scientific knowledge will be instrumental in ultimately defeating this disease. As of 2025, the CDC still recommends COVID-19 vaccines for most adults, with a focus on those aged 65 and older or those with high-risk factors.
Hepatitis: Unvaccinated and at Risk
You may want to see also
Explore related products
$18.99 $18.99
The Wuhan Academy of Military Medical Sciences has permission to test a potential formula
The race to develop a vaccine for the novel coronavirus or COVID-19 has been a global effort, with several countries competing to fight the mutated virus. China, Israel, and the US are some of the countries that have been actively working on developing a vaccine.
In this context, the Wuhan Academy of Military Medical Sciences, a Chinese institution, secured permission from the National Products Administration on March 17 to test a potential vaccine formula for COVID-19. The team was led by military biowarfare expert Chen Wei, who stated that they were ready to produce a large-scale vaccine, provided the trials were successful. Chen also assured that they had made preparations for safety, effectiveness, quality control, and mass production. This development came after the Chinese government set a strategic goal to maintain minimal local transmission and protect its population through immunization. The Chinese Ministry of National Defense (MND) announced on March 18 that the vaccine, developed by the Academy of Military Medical Sciences of the People's Liberation Army (PLA), had been approved for clinical trials.
The Wuhan Academy of Military Medical Sciences has played a crucial role in China's response to the COVID-19 outbreak. They have been at the forefront of scientific research and have collaborated with local researchers to develop testing kits and treatment options. Their efforts in vaccine development and clinical trials have been significant, with China making notable progress in vaccine research and development (R&D). The Academy's work has contributed to China's impressive advancement in COVID-19 vaccine R&D, despite its relatively weak innovative and regulatory capacity compared to developed nations.
Vaccines: A Childhood Association or Lifelong Necessity?
You may want to see also
Explore related products
The Israel Biological Research Institute has finished developing a vaccine, but it still requires testing
As of March 2020, scientists at the Israel Biological Research Institute were expected to announce that they had completed development of a vaccine for COVID-19. However, the process was not final and still required a series of tests and experiments that could take months, until the vaccine was confirmed to be effective and safe to use.
The vaccine development process typically involves three stages of clinical trials. The first phase involves testing a small group of healthy volunteers who are monitored for safety aspects and side effects. The second phase involves testing hundreds of people to evaluate the vaccine's effectiveness. The third phase expands to thousands of people and further evaluates the vaccine's effectiveness and safety.
The Israel Biological Research Institute initiated the first phase of their vaccine trials in late October 2020, starting with two initial participants and increasing to 80 over November. If the vaccine was successful in inducing an immune response and no significant side effects were observed, the testing would expand to 960 people in December 2020. The final phase, planned for April or May 2021, would involve injections for 30,000 people. If the vaccine proved effective and safe in this larger population, it would then be approved for full use in the general population.
While Israel made significant progress in vaccine development, it is important to note that creating a safe and effective vaccine requires rigorous testing and multiple phases of clinical trials. This process can take months or even years to ensure the vaccine's safety and efficacy. As of March 2020, the Israel Biological Research Institute's vaccine was still in the initial stages of development and had not yet completed the full clinical trial process. Therefore, while they had made progress towards a vaccine, it was not yet ready for widespread distribution at that time.
Vaccines: Curing Diseases or Preventing Them?
You may want to see also
Explore related products
The vaccine will need to go through three clinical trial stages
Several countries, including China, Israel, and the United States, are in a race to develop a vaccine for COVID-19. While some countries have made preliminary preparations for safety, effectiveness, quality control, and mass production, the development process requires a series of tests and experiments that can take months to ensure the vaccine is safe and effective.
After the three clinical trial phases are complete, the U.S. Food and Drug Administration (FDA) reviews the trial results and conducts additional safety inspections before approving a vaccine for use. The FDA will also inspect the manufacturing facility to ensure reliable and consistent large-scale manufacturing. Phase 4, if included, is a formal, ongoing study to evaluate the new vaccine's safety and effectiveness over a longer period.
It is important to note that participating in any type of clinical trial carries some risk. However, by the time a vaccine reaches Phase 3 clinical trials, it has already been administered to a large group of people, reducing the risk for participants.
Vaccines, Autism, and the Science: What's the Truth?
You may want to see also
Explore related products
The original COVID vaccines were tested on healthy volunteers
The development of a COVID-19 vaccine has been a global effort, with countries including China, Israel, and the US all competing to create an effective formula. The original COVID-19 vaccines were tested on healthy volunteers to ensure their safety and effectiveness. Clinical trials for vaccines compare outcomes such as how many vaccinated versus unvaccinated people get sick, and the results of these trials have shown that COVID-19 vaccines are safe and effective, especially against severe illness, hospitalization, and death. Tens of thousands of volunteers of different ages, races, and ethnicities participated in the trials for the original COVID-19 vaccines.
The clinical trial stage for a vaccine typically involves three phases. The first phase involves testing a small group of healthy volunteers to monitor safety aspects and side effects. Dozens of healthy volunteers participated in the first phase of the Moderna vaccine trial, which began in March 2020 and yielded promising results. The second phase involves testing a larger group of people, typically in the hundreds, to further evaluate the vaccine's safety and effectiveness. The third phase involves testing thousands of people to confirm the vaccine's efficacy and safety before it can be approved for distribution to the public.
In the case of the COVID-19 vaccines, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUAs) to allow for the rapid distribution of vaccines while maintaining high safety standards. The FDA continues to monitor the safety of COVID-19 vaccines as they are distributed outside of clinical trials, and hundreds of millions of people in the United States have received COVID-19 vaccines under intense safety monitoring. The FDA's new regulatory framework for COVID-19 vaccination balances immunologic endpoints with the need for evidence, ensuring timely approval for a broad population while also demanding robust data on low-risk individuals.
While the original COVID-19 vaccines were thoroughly tested on healthy volunteers and have been proven safe and effective, ongoing booster shots may be recommended as new variants emerge. For example, Moderna tested boosters tailored to specific variants, and ran a trial on healthy volunteers which found that a booster of the original strain raised their antibody production against all major variants. As new strains continue to emerge, such as LP.8.1, vaccine producers may need to tailor their shots accordingly.
Who's Eligible for Vaccines in New York State?
You may want to see also
Frequently asked questions
As of 2025, COVID-19 vaccines are available in the US. However, the accessibility of these vaccines is threatened by new measures introduced by the Department of Health and Human Services.
Several countries, including China, Israel, and the US, were involved in the race to develop a vaccine for COVID-19.
The process of developing a vaccine involves three clinical trial stages. The first phase involves testing a small group of healthy volunteers for safety and side effects. The second phase involves testing the vaccine's effectiveness on hundreds of people. The third phase repeats the second phase but with thousands of people.
